Tessera introduces new genome engineering strategy

By The Science Advisory Board staff writers

July 7, 2020 -- Flagship Pioneering, a life science venture capital firm, has introduced Tessera Therapeutics -- a new biotechnology company that will use its Gene Writing technology to cure diseases.

The Gene Writing platform addresses key limitations of gene therapy and gene editing techniques. The new technology can efficiently insert genes and exons, introduce small insertions or deletions, or change single or multiple DNA base pairs. This could help fix errors associated with monogenic disorders (caused by variation in a single gene) or allow precise gene regulation in other complex diseases (neurodegenerative diseases, autoimmune disorders, and metabolic diseases).

The technology was developed by a collaboration of Massachusetts Institute of Technology researchers and scientists at Flagship Labs. Tessera was founded in 2018 to create a platform that could design, make, and launch Gene Writing medicines. Mobile genetic elements -- genetic material that can move around within a genome -- are engineered to create the technology. RNA or DNA templates are used to write therapeutic messages into the genome.

The Gene Writing platform helps overcome many of the limitations of previous genetic medicine approaches. Specifically, it is able to do the following:

  • Make alterations to the genome of somatic cells with minimal reliance upon host DNA repair pathways
  • Permanently add new DNA to dividing cells
  • Write new DNA sequences into the genome by delivering only RNA
  • Allow repeated administration of treatments to dose to effect
Hansa licenses enzyme pretreatment for gene therapy
Hansa Biopharma has entered into an agreement with Sarepta Therapeutics for an exclusive worldwide license to develop and promote imlifidase as a pretreatment...
New labs being built in Philadelphia due to gene, cell therapy demand
Real estate developer MRA Group is building lab spaces in Philadelphia to meet the region's growing demand for cell and gene therapy.
MaxCyte launches Expert cell engineering products
Cell-based medicines and life sciences company MaxCyte has launched a new line of disposable cell engineering products.
Genprex expands gene therapy manufacturing
Genprex has expanded its program to manufacture tumor suppressor candidate 2 (TUSC2) with a new manufacturing agreement with partner Aldevron.
Sexton, BioSpherix collaborate to support cell & gene therapy needs
Sexton Biotechnologies is partnering with BioSpherix Medical on the final steps of downstream bioprocessing, fill-finish.

Copyright © 2020 scienceboard.net

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter